Articles producció científica> Bioquímica i Biotecnologia

The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome

  • Identification data

    Identifier: imarina:5671676
  • Authors:

    Selma M
    González-Sarrías A
    Salas-Salvadó J
    Andrés-Lacueva C
    Alasalvar C
    Örem A
    Tomás-Barberán F
    Espín J
  • Others:

    Author, as appears in the article.: Selma M; González-Sarrías A; Salas-Salvadó J; Andrés-Lacueva C; Alasalvar C; Örem A; Tomás-Barberán F; Espín J
    Department: Bioquímica i Biotecnologia
    URV's Author/s: Salas Salvadó, Jorge
    Keywords: cardiovascular ellagic acid gut microbiota metabotype obesity Cardiovascular Ellagic acid Gut microbiota Metabotype Obesity Polyphenols
    Abstract: © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism Background & aims: Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status. Methods: UM was identified using UPLC-ESI-qToF-MS in individuals consuming pomegranate or nuts. The associations between basal CMR factors and the urine urolithin metabolomic signature were explored in 20 healthy normoweight individuals consuming walnuts (30 g/d), 49 healthy overweight-obese individuals ingesting pomegranate extract (450 mg/d) and 25 metabolic syndrome (MetS) patients consuming nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d). Results: Correlations between CMR factors and urolithins were found in overweight-obese individuals. Urolithin-A (mostly present in UM-A) was positively correlated with apolipoprotein A-I (P ≤ 0.05) and intermediate-HDL-cholesterol (P ≤ 0.05) while urolithin-B and isourolithin-A (characteristic from UM-B) were positively correlated with total-cholesterol, LDL-cholesterol (P ≤ 0.001), apolipoprotein B (P ≤ 0.01), VLDL-cholesterol, IDL-cholesterol, oxidized-LDL and apolipoprotein B:apolipoprotein A-I ratio (P ≤ 0.05). In MetS patients, urolithin-A only correlated inversely with glucose (P ≤ 0.05). Statin-treated MetS patients with UM-A showed a lipid profile similar to that of healthy normoweight individuals while a poor response to lipid-lowering therapy was observed in MB patients. Conclusions: UMs are potential CMR biomarkers. Overweight-obese individuals with UM-B are at increased risk of cardiometabolic disease, whereas urolithin-A production could protect against CMR factors. Further research is warranted to explore these associations in larger cohorts and whether the effect of lipid-lowering drugs or ellagitannin-consumption on CMR biomarkers depends on individuals’ UM. Clinical Trial Registry numbers and websites: NCT01916239 (https://clinicaltrials.gov/ct2/show/NCT01916239) and ISRCTN36468613 (http://www.isrctn.com/ISRCTN36468613).
    Thematic Areas: Biotecnología Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Critical care and intensive care medicine Educação física Enfermagem Engenharias iv Farmacia General medicine Interdisciplinar Medicina i Medicina ii Medicina iii Nutrição Nutrition & dietetics Nutrition and dietetics Odontología Química Saúde coletiva
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: jordi.salas@urv.cat
    ISSN: 02615614
    Author identifier: 0000-0003-2700-7459
    Record's date: 2023-02-18
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://www.clinicalnutritionjournal.com/article/S0261-5614(17)30103-6/abstract
    Papper original source: Clinical Nutrition. 37 (3): 897-905
    APA: Selma M; González-Sarrías A; Salas-Salvadó J; Andrés-Lacueva C; Alasalvar C; Örem A; Tomás-Barberán F; Espín J (2018). The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome. Clinical Nutrition, 37(3), 897-905. DOI: 10.1016/j.clnu.2017.03.012
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.1016/j.clnu.2017.03.012
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications
  • Keywords:

    Critical Care and Intensive Care Medicine,Nutrition & Dietetics,Nutrition and Dietetics
    cardiovascular
    ellagic acid
    gut microbiota
    metabotype
    obesity
    Cardiovascular
    Ellagic acid
    Gut microbiota
    Metabotype
    Obesity
    Polyphenols
    Biotecnología
    Ciência de alimentos
    Ciências biológicas i
    Ciências biológicas ii
    Ciências biológicas iii
    Critical care and intensive care medicine
    Educação física
    Enfermagem
    Engenharias iv
    Farmacia
    General medicine
    Interdisciplinar
    Medicina i
    Medicina ii
    Medicina iii
    Nutrição
    Nutrition & dietetics
    Nutrition and dietetics
    Odontología
    Química
    Saúde coletiva
    02615614
  • Documents:

  • Cerca a google

    Search to google scholar